Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Investigational drug for hepatitis C boceprevir achieved significantly higher sustained virologic response rates compared to control

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor.

Published
31 October 2010
From
Digital Journal
Bristol-Myers, Gilead seek AIDS cocktail success in hepatitis C

Bristol-Myers Squibb Co. and Gilead Sciences Inc., makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C. The companies are among about a dozen that are developing drug cocktails more effective, less toxic and easier to take than current therapy.

Published
30 October 2010
From
Bloomberg
High hepatitis C mortality and low clearance rates in HIV/HCV-co-infected patients in France

Mortality rates are high among French patients co-infected with HIV and hepatitis C, investigators report in BMC Infectious Diseases. Over 40% of deaths were directly attributable to

Published
29 October 2010
By
Michael Carter
Hepatitis C drug pipeline analysis and market forecasts to 2016

GlobalData has released a pharmaceutical and healthcare report, "Hepatitis C-Drug Pipeline Analysis and Market Forecasts to 2016".

Published
27 October 2010
From
Press release
Vertex Pharmaceuticals highlights progress in hepatitis C drug development

Vertex Pharmaceuticals issues a status report on plans for licensing of its HCV protease inhibitor telaprevir, and announces details of further studies.

Published
27 October 2010
From
Vertex
Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

Published
10 October 2010
From
Eurekalert Medicine & Health
NICE’s publishes 200th guidance to better tackle Hepatitis C

The new guidance updates existing recommendations on the use of peginterferon alfa and ribavirin, allowing for wider use and, if appropriate, shorter treatment regimens for patients with the disease.

Published
27 September 2010
From
Pharma Times
Taribavirin offers a safe, effective alternative for chronic hepatitis C

Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response in patients with chronic hepatitis C.

Published
22 September 2010
From
Eurekalert Medicine & Health
Partial hep C treatment response offers health benefits

Even a partial response to hepatitis C virus (HCV) therapy confers significant health benefits to people coinfected with both HIV and HCV, though not as much as a full response. These data were presented September 14 at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

Published
20 September 2010
From
AIDSMeds.com
HIV/HCV co-infected women more likely to stop HCV therapy

HIV/hepatitis C-co-infected women were more likely to experience side-effects that lead to the discontinuation or modification of hepatitis C therapy, US investigators report in the online edition of

Published
14 September 2010
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.